|
|
Advertisement
|
|
Fourth Site Approved for Enrollment in TRIBUTE Trial
Washington, DC (9 December 2025) – The Society of Interventional Oncology (SIO) is pleased to announce that Baptist Health South Florida has been approved to commence enrollment in the society's second clinical trial, TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy. Baptist Health South Florida will be led by site principal investigators Gina Landinez, MD, and Jean Pierre Obeid, MD.
The TRIBUTE study clinical leadership includes Jack Jennings, MD, PhD, and Clifford Robinson, MD, at Washington University School of Medicine, St. Louis, and Sean Tutton, MD, and James Urbanic, MD, at UCSD. "We are excited to share that Baptist Health South Florida is our fourth site activated and is ready for patient enrollment in the TRIBUTE Trial," said Jennings. "We look forward to announcing other sites in the U.S. as they are approved for enrollment."
The TRIBUTE study is collectively supported by the study's Exclusive Pioneer Trial Partner, Varian, a Siemens Healthineers Company
, the study's Catalyst Trial Partner, Stryker, Inc., and the study's Advocate Trial Partner, Boston Scientific Corporation.
This is the first prospective, multi-center study to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study. Upon completion, the study will enroll 120 subjects from across sites in the United States.
Percutaneous ablation and RT have different mechanisms of alleviating pain and causing tumor death that may work synergistically. Radiation therapy is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients. Percutaneous ablation, a minimally invasive therapy for painful metastatic bone disease, can be performed with thermal modalities (e.g., radiofrequency, microwave, cryoablation) and requires minimal recovery.
|
Advertisement
|
|
Register for Our Upcoming Webinars
RMSS Talk of the Season: Training Without Borders: International IR Pathways
Monday, 15 December | 6:00 - 7:00 p.m. ET
Join us for Training Without Borders: International IR Pathways, a dynamic discussion designed to help U.S. IR trainees understand global training models, navigate logistical considerations for international experiences, and appreciate cultural differences in global IR practice. Featuring Dr. Stephen Hunt and Dr. Fabian Laage Gaupp, and Dr. Takeshi Wada, this session will provide firsthand insights into building meaningful, collaborative IR opportunities abroad. Learning Objectives 1. Understand key differences between U.S. and international IR training pathways and practice environments. 2. Recognize cultural and clinical practice perspectives that shape international IR training and collaboration.
Register Now
Webinar Series Sponsored By:
Did you miss any of our November webinars? You're in luck — you can catch them all on demand. Visit our webinar library to watch anytime.
Browse On-Demand Webinars
|
|
Renew Your 2026 Membership Today
Renew your SIO membership and continue building momentum in your interventional oncology career. Stay connected to exclusive education, timely insights, and a strong professional community that supports your growth. Renew by 31 December 2025 to keep your benefits active for 2026.
Renew Now
Not an SIO member? Demonstrate your commitment to the IO field and to moving your own career forward by joining today! As an SIO member, you'll benefit immediately from the latest education and research, event discounts, exclusive opportunities to earn CME credit, and more.
|
Advertisement
|
Promoted by Medtronic
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases. Learn More
|
|
Register Today to Secure Your Spot
Elevate your expertise in Savannah, Georgia, USA, 4–8 February, at the SIO 2026 Annual Scientific Meeting. Experience bold science, innovative education, and hands-on training that will elevate your practice and expand the future of interventional oncology.
Register Today
|
Submit Your Late Breaking Abstract!
SIO is now accepting late breaking abstract submissions for the SIO 2026 Annual Scientific Meeting in Savannah, Georgia, USA. If your research was not ready for the original October deadline, you can still share new data and emerging results with the interventional oncology community. Submit by Friday, 2 January, and review the full guidelines on the Abstracts page.
|
New in 2026: Palliative Pain in Cancer Patients Master Class
Separate Registration Required
Discover new ways to care for patients in pain during this immersive half-day program on Wednesday, 4 February, held in conjunction with the SIO 2026 Annual Scientific Meeting.
Learn from global leaders in interventional oncology as you explore real cases, advanced techniques, and hands-on training designed to strengthen your clinical skills and elevate your practice.
Learn More
The RISE Forum
Separate Registration Required
Be part of the RISE Forum: Research, Innovation & Science Exchange on Wednesday, 4 February in Savannah.
SIO is also offering the brand-new RISE Forum Scholarship, open to students, trainees, and early-career researchers passionate about IO. Selected recipients will be invited by 20 October 2025. The application period is now closed.
Reserve your spot, and join a community committed to improving cancer pain management.
Learn More
|
|
Build Protocols. Get Funded. Lead Research.
Applications are now open to participate in the first-ever Interventional Oncology Clinical Trials Methodology Workshop, a new initiative of SIO's Clinical Trial Collaborative.
Held in a small-group setting at the University of Pennsylvania, this immersive five-day workshop — 19-23 May 2026 — combines expert-led sessions, protocol development groups, and one-on-one mentorship to foster collaboration and address the unique challenges of interventional oncology research.
Designed for interventional oncologists and clinical researchers, the workshop equips participants with the skills to effectively design, write, and execute clinical trials.
Learn More and Apply
About the Workshop
This workshop offers a deep dive into clinical trial design across all phases, with insights into regulatory frameworks, statistical principles, and cutting-edge methodologies like AI integration, cost-effectiveness analysis, and pragmatic trials. Participants will also explore how to incorporate biomarkers, imaging, and real-world data, while learning strategies for multi-center collaboration and securing funding.
Expert faculty will lead one-on-one mentoring and small-group discussions, supporting participants as they finalize their trial protocol through the five-day workshop.
Attend on Scholarship
Seats are limited for this unique educational experience! Invited participants will receive:
- Complimentary registration
- Complimentary five-night stay at The Study at University City
- $750 travel stipend
Apply For Scholarship
|
|
IO Insights
The Society of Interventional Oncology
2001 K Street NW, 3rd Floor North | Washington, DC 20006 USA
202-367-1164 | Contact Us
www.sio-central.org
|
|
|
|
|
|